Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miricorilant PK with Fluvoxamine in Healthy Subjects
NCT05712265Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Jan 2023
- Primary completion
- Feb 2023
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of miricorilant in Nonalcoholic steatohepatitis (NASH) and antipsychotic-induced weight gain (AIWG), sponsored by Corcept Therapeutics. Primary endpoints: Maximum observed plasma concentration of miricorilant, Area under the curve from time zero to the time of last measurable plasma concentration of miricorilant and 1 more. Started Jan 2023; status: completed.
02
Drugs
miricorilant
03
Conditions
Nonalcoholic steatohepatitis (NASH)antipsychotic-induced weight gain (AIWG)
Beyond the preview
Go deeper on NCT05712265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712265.